Source: La Republica Author: Wilson siancas

Servando García García assures that the antiparasitic reduces the symptoms of COVID-19. In addition, he emphasizes that he consumes the drug preventively and under medical prescription.

The consumption of ivermectin as an early treatment against COVID-19, was supported and promoted by the regional governor of Piura , Servando García Correa, despite the lack of scientific evidence that certifies the efficacy of the drug against the disease.

The regional authority said that the antiparasitic reduces the symptoms of COVID-19, and assured that it currently consumes it, and has obtained good results.

“The use of ivermectin serves to reduce symptoms always under medical prescription. We don’t have the vaccine, but we do have ivermectin. He took it in a preventive way and to this day I have not had any problems, “said the regional authority .

In that sense, it supported the decision of the Ministry of Health (Minsa) and EsSalud to include ivermectin again in the outpatient treatment kit for COVID-19 patients . Servando García ordered the promotion of the antiparasitic in the panels of the regional entity.







Related: IVERMECTIN IS INCLUDED IN COVID-19 TREATMENT AGAIN: Peru

Ivermectin for Covid-19: Database of all Ivermectin COVID-19 studies – 35 trials and growing

Use of Ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt : A randomised clinical trial

COVID-19: A realistic approach to community management – HCQ & IVM in concert with vaccination

Not Using Ivermectin, One Year In, Is Unethical And Immoral

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19 infection includes HCQ & Ivermectin

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »